ArticleClinical drug investigation2026

Healthcare Cost Patterns in CDK4/6 Inhibitor-Treated HR+/HER2- Metastatic Breast Cancer.

Munenobu Kashiwa et al.PubMed ↗Publisher ↗

No numbers read from the abstract.